Filter
278
Filtered Results: 278
Text search:
antipsychotic
Featured
Recommendations
50
New Publications
45
Language
Document type
No document type
195
Guidelines
35
Manuals
23
Studies & Reports
13
Fact sheets
5
Training Material
4
Brochures
1
Resource Platforms
1
Strategic & Response Plan
1
Countries / Regions
Ethiopia
11
South Africa
8
Global
7
Eastern Europe
7
India
6
Kenya
5
Ukraine
5
Nigeria
4
Uganda
4
Russia
4
Zambia
4
Nepal
3
Sierra Leone
3
Western and Central Europe
3
Burkina Faso
2
Zimbabwe
2
Philippines
2
Africa
2
Haiti
2
Latin America and the Carribbean
2
Jamaica
2
Bangladesh
2
Botswana
2
South Sudan
2
Ghana
1
Rwanda
1
Syria
1
Singapore
1
Senegal
1
Afghanistan
1
Peru
1
Guinea
1
Asia
1
Venezuela
1
Lithuania
1
Germany
1
Congo, Democratic Republic of
1
Middle East and North Africa
1
South–East Asia Region
1
Eastern Europe and Central Asia
1
Paraguay
1
United Kingdom
1
Brazil
1
Central African Republic
1
Chad
1
Eswatini/ Swaziland
1
Authors & Publishers
Publication Years
Category
Countries
68
Clinical Guidelines
22
Public Health
13
Women & Child Health
4
Key Resources
3
Capacity Building
2
Pharmacy & Technologies
2
Toolboxes
Mental Health
174
Pharmacy
15
TB
10
COVID-19
8
NCDs
5
Refugee
4
Disability
4
Caregiver
4
Conflict
4
Global Health Education
4
Planetary Health
3
HIV
2
Ebola & Marburg
2
Natural Hazards
1
NTDs
1
Other disorders
Chapter H.5.1
Q1: In individuals with psychotic disorders (including schizophrenia), are antipsychotic drugs safe and effective?
Q7: In individuals with bipolar mania, are a) antipsychotics, b) mood stabilizers (lithium carbonate, valproate, and carbamazepine) effective and safe
Q8. SCOPING QUESTION: In people with bipolar disorders who require maintenance treatment, are a) antipsychotics or b) mood stabilizers (lithium, valproate or carbamazepine) effective and safe?
Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug treatment be continued after remission in order to allow for the best outcomes?
Otros trastornos
Capítulo H.5.1
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Iván Olle Llopis
Q5.SCOPING QUESTION: In individuals with psychotic disorders (including schizophrenia) who require long-term antipsychotic treatment, what is the safety and role of depot antipsychotic medication?
Q4: In individuals with long term and/or recurrent psychotic disorders (including schizophrenia), should individuals be maintained on pharmacotherapy indefinitely or withdrawn from treatment in order to allow for the best outcomes?
Second-generation antipsychotic medications for psychotic disorders (including schizophrenia)
recommended
Q14. SCOPING QUESTION: In adults with psychotic disorders (including schizophrenia), what is the comparative effectiveness and safety of second-generation antipsychotic medications?
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
Schizophr Bull. 2014 Jan;40(1):192-213. doi: 10.1093/schbul/sbs150. Epub 2012 Dec 17.
Q2: In individuals with psychotic disorders (including schizophrenia), is the use of two or more antipsychotic medications concurrently more effective and safer than the use of one antipsychotic only?
Q6: In individuals with psychotic disorders (including schizophrenia) who require long term antipsychotic treatment, are anticholinergic medications more effective in preventing or reducing extrapyramidal side-effects and/or improving treatment adherence than placebo/treatment as usual?
Accessed April 16, 2019
Sci Rep. 2016; 6: 25920. Published online 2016 May 16. doi: 10.1038/srep25920
Fourth Edition
Q15. SCOPING QUESTION: Is pharmacological intervention effective and safe for treatment of psychotic disorders in adolescents (including schizophrenia and bipolar disorder)?
Ethiopia National Essential Medicine List
recommended
6 edition
